Larry Dillaha, M.D. is an experienced executive with 20 years of experience in the pharmaceutical industry. Prior to joining Melt Pharmaceuticals as Chief Executive Officer in June 2021, he served as the Chief Medical Officer of Harrow Health, where he managed the clinical development of all Harrow drug candidates throughout its portfolio of businesses. Previously, he served as Chief Executive Officer of both Repros Therapeutics and CavtheRx, an inception stage biotechnology company, as well as Chief Operating Officer and Chief Medical Officer for other specialty pharmaceutical companies. Dr. Dillaha has served as the senior leader on numerous FDA-approved 505(b)(2) development programs across a broad range of therapeutic areas, generating more than $1 billion in revenues. Dr. Dillaha earned an M.D. degree from the University of Tennessee, Memphis.
Brad Osborne is an executive with 20 years of extensive finance and accounting experience. Prior to joining Melt Pharmaceuticals as Chief Financial Officer in February 2022, Mr. Osborne worked for 10 years with Precigen, Inc. (formerly Intrexon Corporation), a Nasdaq-listed discovery and clinical-stage biopharmaceutical company, having served the last five years as Vice President, Finance and Accounting. During his tenure with Precigen, he managed all finance and accounting activities related to Precigen’s initial public offering, multiple private and public equity and debt capital raises, SEC reporting and compliance, mergers and acquisitions, divestitures, and budgeting. Mr. Osborne previously served as Accounting Director, Portfolio Investments, for Third Security, LLC, a manager of a portfolio of biotechnology companies, and he began his career with public accounting firm KPMG LLP. Mr. Osborne has a B.S. in Accounting from Virginia Tech and is a certified public accountant.
Giovanni De Castro has over 25 years of experience in clinical operations where he provided clinical development and operational support, including strategic planning, risk assessment, vendor relations, clinical trial design/program metrics, and business development. Prior to joining Melt Pharmaceuticals as Senior Director of Clinical Operations in November 2021, he served in clinical leadership positions of increasing responsibility at Mitsubishi Tanabe Pharma Holdings America, Inc, INSYS Development Company, Inc., Shionogi USA, Inc., Hoffman-La Roche, and Sanofi-Aventis. Mr. De Castro has a B.S. in Science from Fairleigh Dickinson University.